Skip to main
LCTX

LCTX Stock Forecast & Price Target

LCTX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lineage Cell Therapeutics is a clinical-stage biotechnology company that boasts a strong pipeline of potentially groundbreaking therapies and a proprietary cell-based manufacturing platform. With increasing revenue and growing operational progress, the company has seen a net income for the first quarter in 2025. Upcoming catalysts, such as further clinical data releases and the potential for additional non-dilutive capital, could drive further success for Lineage Cell Therapeutics, making it a promising investment opportunity.

Bears say

Lineage Cell Therapeutics is a clinical-stage biotechnology company with a pipeline focused on degenerative diseases, but its most advanced asset, OpRegen, faces several key risks in clinical/regulatory, financial, commercial, legal/intellectual property, and market share spheres. While the company's partnerships display commitment and have brought in milestone revenue, the milestone's division with the Israel Innovation Authority and Hadasit suggests that its prior funding and collaboration structures have reduced potential net cash benefit. Additionally, OpRegen's positive findings are far from definitive, and trading indications remain slow to emerge.

LCTX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lineage Cell Therapeutics Inc (LCTX) Forecast

Analysts have given LCTX a Strong Buy based on their latest research and market trends.

According to 4 analysts, LCTX has a Strong Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lineage Cell Therapeutics Inc (LCTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.